Karen E Knudsen

List of Publications by Year
in descending order

157	15,919	67	121
papers	citations	h-index	g-index
		13827	17546

160	160	160	21086
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. New England Journal of Medicine, 2015, 373, 1697-1708.	13.9	1,796
2	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell, 2018, 174, 758-769.e9.	13.5	459
3	Prostate cancer. Nature Reviews Disease Primers, 2021, 7, 9.	18.1	434
4	Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1106-15.	3.3	376
5	Dual Roles of PARP-1 Promote Cancer Growth and Progression. Cancer Discovery, 2012, 2, 1134-1149.	7.7	354
6	Tailoring to RB: tumour suppressor status and therapeutic response. Nature Reviews Cancer, 2008, 8, 714-724.	12.8	311
7	AR, the cell cycle, and prostate cancer. Nuclear Receptor Signaling, 2008, 6, nrs.06001.	1.0	300
8	A Hormoneâ€“DNA Repair Circuit Governs the Response to Genotoxic Insult. Cancer Discovery, 2013, 3, 1254-1271.	7.7	294
9	Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer. Clinical Cancer Research, 2009, 15, 4792-4798.	3.2	275
10	The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. Journal of Clinical Investigation, 2010, 120, 4478-4492.	3.9	268
11	Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocrine-Related Cancer, 2011, 18, 333-345.	1.6	256
12	An evaluation of evidence for the carcinogenic activity of bisphenol A. Reproductive Toxicology, 2007, 24, 240-252.	1.3	249
13	Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends in Endocrinology and Metabolism, 2010, 21, 315-324.	3.1	248
14	The meaning of p16^{ink4a}expression in tumors. Cell Cycle, 2011, 10, 2497-2503.	1.3	240
15	<i>PCAT-1</i>, a Long Noncoding RNA, Regulates BRCA2 and Controls Homologous Recombination in Cancer. Cancer Research, 2014, 74, 1651-1660.	0.4	237
16	Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of <i>BRCA2</i> Reversion Mutations Associated with Resistance to PARP Inhibitors. Cancer Discovery, 2017, 7, 999-1005.	7.7	223
17	The Long Non-Coding RNA PCAT-1 Promotes Prostate Cancer Cell Proliferation through cMyc. Neoplasia, 2014, 16, 900-908.	2.3	216
18	RB-Dependent S-Phase Response to DNA Damage. Molecular and Cellular Biology, 2000, 20, 7751-7763.	1.1	213

#	Article	IF	Citations
19	Development and Validation of a Scalable Next-Generation Sequencing System for Assessing Relevant Somatic Variants in Solid Tumors. Neoplasia, 2015, 17, 385-399.	2.3	212
20	Beyond DNA Repair: DNA-PK Function in Cancer. Cancer Discovery, 2014, 4, 1126-1139.	7.7	202
21	The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. Clinical Cancer Research, 2019, 25, 6916-6924.	3.2	200
22	The DNA methylation landscape of advanced prostate cancer. Nature Genetics, 2020, 52, 778-789.	9.4	198
23	The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. Journal of Clinical Investigation, 2007, 117, 218-228.	3.9	178
24	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. Journal of Clinical Oncology, 2020, 38, 2798-2811.	0.8	170
25	Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. Journal of Clinical Oncology, 2018, 36, 991-999.	0.8	169
26	Multiple G1 Regulatory Elements Control the Androgen-dependent Proliferation of Prostatic Carcinoma Cells. Journal of Biological Chemistry, 1998, 273, 20213-20222.	1.6	165
27	RB-pathway disruption in breast cancer. Cell Cycle, 2010, 9, 4153-4163.	1.3	163
28	FOXA1: master of steroid receptor function in cancer. EMBO Journal, 2011, 30, 3885-3894.	3.5	162
29	Alternative Splicing of the Cyclin D1 Proto-Oncogene Is Regulated by the RNA-Binding Protein Sam68. Cancer Research, 2010, 70, 229-239.	0.4	157
30	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. Journal of Clinical Oncology, 2018, 36, 414-424.	0.8	155
31	Genomic Prostate Cancer Classifier Predicts Biochemical Failure and Metastases in Patients After Postoperative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2014, 89, 1038-1046.	0.4	149
32	DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis. Cancer Cell, 2015, 28, 97-113.	7.7	148
33	Transcriptional Roles of PARP1 in Cancer. Molecular Cancer Research, 2014, 12, 1069-1080.	1.5	144
34	Cancer and the Circadian Clock. Cancer Research, 2019, 79, 3806-3814.	0.4	140
35	The xenoestrogen bisphenol A induces inappropriate androgen receptor activation and mitogenesis in prostatic adenocarcinoma cells. Molecular Cancer Therapeutics, 2002, 1, 515-24.	1.9	130
36	Cyclin D1: Mechanism and Consequence of Androgen Receptor Co-repressor Activity. Journal of Biological Chemistry, 2002, 277, 2207-2215.	1.6	128

#	Article	IF	Citations
37	Targeting the p300/CBP Axis in Lethal Prostate Cancer. Cancer Discovery, 2021, 11, 1118-1137.	7.7	124
38	Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 2190-2195.	3.3	123
39	BAF57 Governs Androgen Receptor Action and Androgen-Dependent Proliferation through SWI/SNF. Molecular and Cellular Biology, 2005, 25, 2200-2215.	1.1	117
40	Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function. Molecular Cell, 2015, 58, 925-934.	4.5	114
41	Ex vivo culture of human prostate tissue and drug development. Nature Reviews Urology, 2013, 10, 483-487.	1.9	111
42	Hus1p, a conserved fission yeast checkpoint protein, interacts with Rad1p and is phosphorylated in response to DNA damage. EMBO Journal, 1998, 17, 2055-2066.	3.5	110
43	Hijacking the Chromatin Remodeling Machinery: Impact of<i>SWI/SNF</i>Perturbations in Cancer. Cancer Research, 2009, 69, 8223-8230.	0.4	102
44	Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. Cell Reports, 2017, 19, 2045-2059.	2.9	99
45	Targeting cell cycle and hormone receptor pathways in cancer. Oncogene, 2013, 32, 5481-5491.	2.6	98
46	USP22 Regulates Oncogenic Signaling Pathways to Drive Lethal Cancer Progression. Cancer Research, 2014, 74, 272-286.	0.4	98
47	Compensation of BRG-1 Function by Brm. Journal of Biological Chemistry, 2002, 277, 4782-4789.	1.6	97
48	Molecular Pathogenesis and Progression of Prostate Cancer. Seminars in Oncology, 2013, 40, 244-258.	0.8	96
49	Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import. Cell, 2018, 174, 1200-1215.e20.	13.5	96
50	A patientâ€derived explant (<scp>PDE</scp>) model of hormoneâ€dependent cancer. Molecular Oncology, 2018, 12, 1608-1622.	2.1	94
51	Differential Requirement of SWI/SNF for Androgen Receptor Activity. Journal of Biological Chemistry, 2003, 278, 30605-30613.	1.6	93
52	Evidence for Efficacy of New Hsp90 Inhibitors Revealed by <i>Ex Vivo</i> Culture of Human Prostate Tumors. Clinical Cancer Research, 2012, 18, 3562-3570.	3.2	92
53	Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E9298-E9307.	3.3	91
54	Novel Actions of Next-Generation Taxanes Benefit Advanced Stages of Prostate Cancer. Clinical Cancer Research, 2015, 21, 795-807.	3.2	89

#	Article	IF	Citations
55	2,3,7,8-Tetrachlorodibenzo-p-dioxin Blocks Androgen-Dependent Cell Proliferation of LNCaP Cells through Modulation of pRB Phosphorylation. Molecular Pharmacology, 2004, 66, 502-511.	1.0	85
56	Retinoblastoma Tumor Suppressor: Where Cancer Meets the Cell Cycle. Experimental Biology and Medicine, 2006, 231, 1271-1281.	1.1	85
57	Cyclin D1 Splice Variants: Polymorphism, Risk, and Isoform-Specific Regulation in Prostate Cancer. Clinical Cancer Research, 2009, 15, 5338-5349.	3.2	84
58	Differential impact of RB status on E2F1 reprogramming in human cancer. Journal of Clinical Investigation, 2017, 128, 341-358.	3.9	83
59	Retinoblastoma Tumor Suppressor Status Is a Critical Determinant of Therapeutic Response in Prostate Cancer Cells. Cancer Research, 2007, 67, 6192-6203.	0.4	77
60	MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer. Clinical Cancer Research, 2018, 24, 4201-4214.	3.2	77
61	The Epigenetic Modifier Ubiquitin-specific Protease 22 (USP22) Regulates Embryonic Stem Cell Differentiation via Transcriptional Repression of Sex-determining Region Y-box 2 (SOX2). Journal of Biological Chemistry, 2013, 288, 24234-24246.	1.6	74
62	AR function in promoting metastatic prostate cancer. Cancer and Metastasis Reviews, 2014, 33, 399-411.	2.7	73
63	Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancer. Molecular Cancer Therapeutics, 2006, 5, 3181-3190.	1.9	72
64	The SWI/SNF ATPase Brm Is a Gatekeeper of Proliferative Control in Prostate Cancer. Cancer Research, 2008, 68, 10154-10162.	0.4	71
65	Targeting the BAF57 SWI/SNF Subunit in Prostate Cancer: A Novel Platform to Control Androgen Receptor Activity. Cancer Research, 2008, 68, 4551-4558.	0.4	71
66	Identification of ASF/SF2 as a Critical, Allele-Specific Effector of the Cyclin D1b Oncogene. Cancer Research, 2010, 70, 3975-3984.	0.4	71
67	Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing. Prostate, 2019, 79, 333-339.	1.2	69
68	Detection of Activating Estrogen Receptor Gene (<i>ESR1</i>) Mutations in Single Circulating Tumor Cells. Clinical Cancer Research, 2017, 23, 6086-6093.	3.2	68
69	Androgen receptor corepressors and prostate cancer. Endocrine-Related Cancer, 2006, 13, 979-994.	1.6	67
70	RB Loss Promotes Prostate Cancer Metastasis. Cancer Research, 2017, 77, 982-995.	0.4	67
71	Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status. Cancer Research, 2005, 65, 54-65.	0.4	67
72	Cyclin A Is a Functional Target of Retinoblastoma Tumor Suppressor Protein-mediated Cell Cycle Arrest. Journal of Biological Chemistry, 1999, 274, 27632-27641.	1.6	66

#	Article	IF	Citations
73	Cyclin D1b Is Aberrantly Regulated in Response to Therapeutic Challenge and Promotes Resistance to Estrogen Antagonists. Cancer Research, 2008, 68, 5628-5638.	0.4	65
74	A central domain of cyclin D1 mediates nuclear receptor corepressor activity. Oncogene, 2005, 24, 431-444.	2.6	63
75	Specificity of cyclin D1 for androgen receptor regulation. Cancer Research, 2003, 63, 4903-13.	0.4	63
76	The cyclin D1b splice variant: an old oncogene learns new tricks. Cell Division, 2006, 1, 15.	1.1	62
77	The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair. Nature Communications, 2021, 12, 401.	5.8	60
78	Posttranscriptional Regulation of <i>PARG</i> mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors. Cancer Research, 2017, 77, 5011-5025.	0.4	59
79	Cellular rewiring in lethal prostate cancer: the architect of drug resistance. Nature Reviews Urology, 2020, 17, 292-307.	1.9	59
80	The retinoblastoma tumor suppressor inhibits cellular proliferation through two distinct mechanisms: inhibition of cell cycle progression and induction of cell death. Oncogene, 1999, 18, 5239-5245.	2.6	57
81	Nuclear Targeting of Cyclin-Dependent Kinase 2 Reveals Essential Roles of Cyclin-Dependent Kinase 2 Localization and Cyclin E in Vitamin D-Mediated Growth Inhibition. Endocrinology, 2010, 151, 896-908.	1.4	54
82	Retinoblastoma Tumor Suppressor Protein Signals through Inhibition of Cyclin-Dependent Kinase 2 Activity To Disrupt PCNA Function in S Phase. Molecular and Cellular Biology, 2001, 21, 4032-4045.	1.1	53
83	Linking DNA Damage and Hormone Signaling Pathways in Cancer. Trends in Endocrinology and Metabolism, 2016, 27, 216-225.	3.1	52
84	PARPâ€1 regulates DNA repair factor availability. EMBO Molecular Medicine, 2018, 10, .	3.3	52
85	PARP Inhibitors in Prostate Cancer. Current Treatment Options in Oncology, 2017, 18, 37.	1.3	50
86	Targeted Radiosensitization of ETS Fusion-Positive Prostate Cancer through PARP1 Inhibition. Neoplasia, 2013, 15, 1207-IN36.	2.3	49
87	Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer. Expert Review of Endocrinology and Metabolism, 2011, 6, 483-493.	1.2	48
88	mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer. Endocrine-Related Cancer, 2012, 19, 1-12.	1.6	48
89	Targeting PARP-1 Allosteric Regulation Offers Therapeutic Potential against Cancer. Cancer Research, 2014, 74, 31-37.	0.4	47
90	Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. JAMA Oncology, 2016, 2, 471.	3.4	46

#	Article	IF	Citations
91	USP22 Functions as an Oncogenic Driver in Prostate Cancer by Regulating Cell Proliferation and DNA Repair. Cancer Research, 2020, 80, 430-443.	0.4	46
92	The AR dependent cell cycle: Mechanisms and cancer relevance. Molecular and Cellular Endocrinology, 2012, 352, 34-45.	1.6	45
93	Models of neuroendocrine prostate cancer. Endocrine-Related Cancer, 2015, 22, R33-R49.	1.6	45
94	RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2019, 25, 687-697.	3.2	43
95	Optimizing the Use of Telemedicine in Oncology Care: Postpandemic Opportunities. Clinical Cancer Research, 2021, 27, 933-936.	3.2	42
96	Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression. Molecular Cancer Research, 2015, 13, 1591-1601.	1.5	41
97	DNA Damage Response in Prostate Cancer. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a030486.	2.9	40
98	RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease. Cancer Discovery, 2021, 11, 2334-2353.	7.7	40
99	Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer. Nature Reviews Urology, 2011, 8, 562-568.	1.9	39
100	Functional Specificities of Brm and Brg-1 Swi/Snf ATPases in the Feedback Regulation of Hepatic Bile Acid Biosynthesis. Molecular and Cellular Biology, 2009, 29, 6170-6181.	1.1	38
101	Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types. Clinical Cancer Research, 2019, 25, 4290-4299.	3.2	38
102	Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes. Journal of Clinical Investigation, 2013, 123, 493-508.	3.9	38
103	Cyclin D1 Is a Selective Modifier of Androgen-dependent Signaling and Androgen Receptor Function*. Journal of Biological Chemistry, 2011, 286, 8117-8127.	1.6	37
104	Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. European Urology Oncology, 2018, 1, 325-337.	2.6	37
105	Unique Bisphenol A Transcriptome in Prostate Cancer: Novel Effects on ERÎ² Expression That Correspond to Androgen Receptor Mutation Status. Environmental Health Perspectives, 2007, 115, 1646-1653.	2.8	36
106	Progesterone Receptorâ€"Cyclin D1 Complexes Induce Cell Cycleâ€"Dependent Transcriptional Programs in Breast Cancer Cells. Molecular Endocrinology, 2014, 28, 442-457.	3.7	36
107	Targeting Pioneering Factor and Hormone Receptor Cooperative Pathways to Suppress Tumor Progression. Cancer Research, 2012, 72, 1248-1259.	0.4	35
108	Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Nonâ€"Small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 1402-1414.	3.2	34

#	Article	IF	Citations
109	The Complex Role of AR Signaling After Cytotoxic Insult: Implications for Cell Cycle Based Chemotherapeutics. Cell Cycle, 2007, 6, 1307-1313.	1.3	32
110	Aberrant BAF57 Signaling Facilitates Prometastatic Phenotypes. Clinical Cancer Research, 2013, 19, 2657-2667.	3.2	32
111	Sigma1 Targeting to Suppress Aberrant Androgen Receptor Signaling in Prostate Cancer. Cancer Research, 2017, 77, 2439-2452.	0.4	32
112	Cell cycle-coupled expansion of AR activity promotes cancer progression. Oncogene, 2017, 36, 1655-1668.	2.6	32
113	SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors. Science Advances, 2019, 5, eaax6352.	4.7	31
114	Cell-cycle-dependent regulation of androgen receptor function. Endocrine-Related Cancer, 2015, 22, 249-264.	1.6	30
115	Decreased local immune response and retained HPV gene expression during chemoradiotherapy are associated with treatment resistance and death from cervical cancer. International Journal of Cancer, 2020, 146, 2047-2058.	2.3	26
116	Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies. Clinical Cancer Research, 2019, 25, 5623-5637.	3.2	23
117	Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer. Oncogene, 2009, 28, 1016-1027.	2.6	22
118	Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas <i>In Vivo</i> and <i>Ex Vivo</i>. Molecular Cancer Therapeutics, 2018, 17, 84-95.	1.9	22
119	Mitogenic Action of the Androgen Receptor Sensitizes Prostate Cancer Cells to Taxane-Based Cytotoxic Insult. Cancer Research, 2006, 66, 11998-12008.	0.4	21
120	DNA-PKcs: A Targetable Protumorigenic Protein Kinase. Cancer Research, 2022, 82, 523-533.	0.4	21
121	The Retinoblastoma Tumor Suppressor Modulates DNA Repair and Radioresponsiveness. Clinical Cancer Research, 2014, 20, 5468-5482.	3.2	19
122	Consequence of the tumorâ€associated conversion to cyclin D1b. EMBO Molecular Medicine, 2015, 7, 628-647.	3.3	19
123	A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer. Clinical Cancer Research, 2021, 27, 3017-3027.	3.2	19
124	DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway. Clinical Cancer Research, 2019, 25, 5608-5622.	3.2	17
125	Caveolin-1 overexpression enhances androgen-dependent growth and proliferation in the mouse prostate. International Journal of Biochemistry and Cell Biology, 2011, 43, 1318-1329.	1.2	16
126	Differential expression of Î±VÎ²3 and Î±VÎ²6 integrins in prostate cancer progression. PLoS ONE, 2021, 16, e0244985.	1.1	16

#	Article	IF	Citations
127	The Role of Tumor Suppressor Dysregulation in Prostate Cancer Progression. Current Drug Targets, 2013, 14, 460-471.	1.0	16
128	Relevance of pRB Loss in Human Malignancies. Clinical Cancer Research, 2022, 28, 255-264.	3.2	15
129	2,2-Bis(4-Chlorophenyl)-1,1-Dichloroethylene Stimulates Androgen Independence in Prostate Cancer Cells through Combinatorial Activation of Mutant Androgen Receptor and Mitogen-Activated Protein Kinase Pathways. Molecular Cancer Research, 2008, 6, 1507-1520.	1.5	14
130	An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy. International Journal of Cancer, 2019, 144, 1151-1159.	2.3	13
131	Mutant p53 elicits context-dependent pro-tumorigenic phenotypes. Oncogene, 2022, 41, 444-458.	2.6	13
132	Postprostatectomy radiation therapy: an evidence-based review. Future Oncology, 2011, 7, 1429-1440.	1.1	12
133	A Novel Role for DNA-PK in Metabolism by Regulating Glycolysis in Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2022, 28, 1446-1459.	3.2	12
134	The SAGA complex regulates early steps in transcription via its deubiquitylase module subunit USP22. EMBO Journal, 2021, 40, e102509.	3.5	9
135	Not So Fast: Cultivating miRs as Kinks in the Chain of the Cell Cycle. Cancer Cell, 2017, 31, 471-473.	7.7	8
136	Assessing the Coverage of US Cancer Center Primary Catchment Areas. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 955-964.	1.1	8
137	Cyclin D1 goes metabolic. Cell Cycle, 2012, 11, 3534-3534.	1.3	6
138	Novel strategy for disease risk prediction incorporating predicted gene expression and DNA methylation data: a multiâ€phased study of prostate cancer. Cancer Communications, 2021, 41, 1387-1397.	3.7	6
139	Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer. Cancer Research, 2022, 82, 221-234.	0.4	6
140	AMP ed up to treat prostate cancer: novel AMPK activators emerge for cancer therapy. EMBO Molecular Medicine, 2014, 6, 439-441.	3.3	5
141	Basic Science and Molecular Genetics of Prostate Cancer Aggressiveness. Urologic Clinics of North America, 2021, 48, 339-347.	0.8	5
142	Hormone Whodunit: Clues for Solving the Case of Intratumor Androgen Production. Clinical Cancer Research, 2014, 20, 5343-5345.	3.2	3
143	Improvement in Therapeutic Efficacy and Reduction in Cellular Toxicity: Introduction of a Novel Anti-PSMA-Conjugated Hybrid Antiandrogen Nanoparticle. Molecular Pharmaceutics, 2018, 15, 1778-1790.	2.3	3
144	Double Trouble: Concomitant RB1 and BRCA2 Depletion Evokes Aggressive Phenotypes. Clinical Cancer Research, 2020, 26, 1784-1786.	3.2	3

#	Article	IF	Citations
145	Androgen Mediated Regulation of the G1-S Transition in Prostate Cancer. , 2002, , 91-110.		2
146	A tale of three PKCs. Cell Cycle, 2011, 10, 379-379.	1.3	1
147	IGF2 revs the steroidogenesis engine. Endocrine-Related Cancer, 2013, 20, C19-C21.	1.6	1
148	There and Back Again: The Middle Earth of DNA Repair. Molecular Cancer Research, 2016, 14, 895-897.	1.5	1
149	Expanding Role of Germline DNA Repair Alterations in Prostate Cancer Risk and Early Onset. European Urology, 2019, 76, 338-339.	0.9	1
150	The Quandary of DNA-Based Treatment Assessment in De Novo Metastatic Prostate Cancer in the Era of Precision Oncology. Journal of Personalized Medicine, 2021, 11, 330.	1.1	1
151	Androgen-mediated Control of the Cyclin D1-RB Axis: Implications for Prostate Cancer. Research and Perspectives in Endocrine Interactions, 2008, , 63-81.	0.2	1
152	Beyond the Cell Cycle: Implications of D-type Cyclin Deregulation in Prostate Cancer. , 2013, , 461-477.		0
153	Middlegame Theory, Cancer Style: A Message from the Editor-in-Chief. Molecular Cancer Research, 2013, 11, 3-4.	1.5	0
154	Fusing Transcriptomics to Progressive Prostate Cancer. American Journal of Pathology, 2014, 184, 2608-2610.	1.9	0
155	Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report. Urology Case Reports, 2016, 9, 51-54.	0.1	0
156	Abstract IA9: Cross talk of the androgen receptor and DNA damage pathways: Molecular and translational prostate cancer relevance. Cancer Research, 2012, 72, IA9-IA9.	0.4	0
157	Splice Variants and Phosphorylated Isoforms of Cyclin D1 in Tumorigenesis. Current Cancer Research, 2018, , 91-109.	0.2	0